Physician profile
Rizwan Alam Bashir
NPI 1467694216
$2,863.07
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.95 · 2021: $245 · 2022: $844 · 2023: $859 · 2024: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,722.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $390.18 | 2022-2024 | Ubrelvy, Qulipta, Botox |
| Ucb, INC. | $306.08 | 2022-2024 | Briviact |
| Pfizer INC. | $219.63 | 2023-2024 | |
| Lilly USA, LLC | $215.29 | 2021-2024 | Emgality, Kisunla, Amyvid |
| Astrazeneca Pharmaceuticals LP | $199.15 | 2021-2023 | Andexxa |
| Medtronic, INC. | $187.57 | 2021 | |
| Amgen INC. | $161.39 | 2022-2024 | Uplizna |
| Alexion Pharmaceuticals, INC. | $140.15 | 2019-2024 | Ultomiris |
| Neurelis, INC. | $109.88 | 2023 | Valtoco |
| Horizon Therapeutics Plc | $105.43 | 2023 | Uplizna |
| Octapharma USA, INC. | $91.39 | 2023-2024 | Panzyga, Octagam Immune Globulin (Human) |
| Eisai INC. | $74.38 | 2024 | |
| Jazz Pharmaceuticals INC. | $73.42 | 2023-2024 | |
| Tanabe Pharma America, INC. | $69.25 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $60.54 | 2023-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $52.05 | 2024 | Gocovri |
| Boston Scientific Corporation | $46.70 | 2022-2024 | Wavewriter Alpha Prime 16 |
| Csl Behring | $40.48 | 2022 | |
| Kyowa Kirin, INC. | $40.34 | 2022 | |
| Genzyme Corporation | $35.76 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.72 | 2023 | Gammagard |
| Sk Life Science, INC. | $28.01 | 2023 | |
| Ge Healthcare | $27.85 | 2024 | |
| Janssen Pharmaceuticals, INC | $27.15 | 2022 | |
| Livanova USA, INC. | $24.76 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Lundbeck LLC | $24.73 | 2024 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $24.24 | 2022 | |
| Grifols USA, LLC | $22.28 | 2022 | |
| Biogen, INC. | $18.52 | 2022 | |
| Acadia Pharmaceuticals INC | $14.75 | 2023 | Daybue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rizwan Bashir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.